LipimetiX Development Overview
- Founded
- 2012
- Status
- Private
- Latest Deal Type
- Corporate
- Financing Rounds
- 2
LipimetiX Development General Information
Description
Developer of drugs for cholesterol-related diseases. The company focuses on the development of drugs for the treatment of refractory hypercholesterolemia, hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases by decreasing arterial cholesterol content and inflammation. The company's technology is based upon a platform of chimeric peptide mimetics of apolipoprotein E, a critical protein that directs cholesterol and triglyceride-rich lipoproteins to receptors on the liver.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Primary Office
- 5 Commonwealth Road
- Suite 2A
- Natick, MA 01760
- United States
+1 (508) 000-0000
LipimetiX Development Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore LipimetiX Development‘s full profile, request access.
Request a free trialLipimetiX Development Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Dennis Goldberg Ph.D | President, Chairman & Co-Founder | ||
| Philip Friden Ph.D | Vice President, Research & Development & Co-Founder |
LipimetiX Development Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore LipimetiX Development‘s full profile, request access.
Request a free trial